Physician profile
Deborah Hatch
NPI 1346644135
$2,404.83
in general payments reported to CMS, 2019-2025
43 companies · $666 in 2025
The $666 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2022: $363 · 2023: $74.89 · 2024: $875 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.65 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $214.37 | 2021-2025 | Rybrevant, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $186.50 | 2022-2025 | Calquence, Enhertu, Imfinzi |
| Pfizer INC. | $155.53 | 2021-2025 | |
| Daiichi Sankyo INC. | $129.95 | 2021-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $119.26 | 2024-2025 | Iclusig, Ninlaro |
| Celgene Corporation | $109.01 | 2021-2025 | Reblozyl |
| Emd Serono, INC. | $100.14 | 2022-2025 | |
| Incyte Corporation | $99.95 | 2024 | |
| Astellas Pharma US INC | $95.94 | 2021-2023 | Padcev |
| Seagen INC. | $93.58 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $77.97 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $74.75 | 2021-2024 | Keytruda |
| Tersera Therapeutics LLC | $66.90 | 2024-2025 | Zoladex |
| Lilly USA, LLC | $65.82 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $61.52 | 2022-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $59.56 | 2025 | Polivy, Tecentriq Hybreza |
| Deciphera Pharmaceuticals INC. | $57.99 | 2021-2024 | Qinlock |
| Glaxosmithkline, LLC. | $54.15 | 2025 | Ojjaara, Blenrep |
| Karyopharm Therapeutics INC. | $46.42 | 2021-2024 | Xpovio |
| Eisai INC. | $43.16 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $39.31 | 2024-2025 | Opdivo |
| Amag Pharmaceuticals, INC. | $31.32 | 2022 | |
| Genmab U.S., INC. | $29.43 | 2024 | Epkinly |
| Gilead Sciences, INC. | $26.75 | 2024 | |
| Recordati_rare_diseases_inc. | $25.90 | 2025 | Enjaymo |
| Sumitomo Pharma America, INC. | $24.71 | 2025 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.67 | 2024 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $21.27 | 2024 | Tavalisse, Rezlidhia |
| Kite Pharma, INC. | $21.18 | 2022 | |
| Array Biopharma INC | $21.00 | 2025 | Lorbrena |
| Pharmaessentia USA Corporation | $20.85 | 2025 | Besremi |
| Cochlear Americas | $20.23 | 2024 | Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant |
| Pharmacyclics LLC, An Abbvie Company | $19.80 | 2021 | |
| Abbvie INC. | $19.36 | 2025 | |
| Pharmacosmos Therapeutics INC. | $19.07 | 2024 | Monoferric |
| Puma Biotechnology, INC. | $18.73 | 2024 | |
| Jazz Pharmaceuticals INC. | $17.93 | 2025 | |
| Sobi, INC | $16.87 | 2025 | |
| G1 Therapeutics, INC. | $16.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.00 | 2024 | Relistor |
| Agios Pharmaceuticals, INC. | $14.93 | 2024 | Pyrukynd |
| Clovis Oncology, INC. | $14.47 | 2022 | |
| Beone Medicines USA, INC. | $13.87 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Hatch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.